Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Status:
Recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of peri-operative gemcitabine,
cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of
gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic
responses.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins